Literature DB >> 28768188

Blockage of Core Fucosylation Reduces Cell-Surface Expression of PD-1 and Promotes Anti-tumor Immune Responses of T Cells.

Masahiro Okada1, Shunsuke Chikuma2, Taisuke Kondo2, Sana Hibino2, Hiroaki Machiyama3, Tadashi Yokosuka3, Miyako Nakano4, Akihiko Yoshimura5.   

Abstract

Programmed cell death 1 (PD-1) is highly expressed on exhausted T cells and inhibits T cell activation. Antibodies that block the interaction between PD-1 and its ligand prevent this inhibitory signal and reverse T cell dysfunction, providing beneficial anti-tumor responses in a substantial number of patients. Mechanisms for the induction and maintenance of high PD-1 expression on exhausted T cells have not been fully understood. Utilizing a genome-wide loss-of-function screening method based on the CRISPR-Cas9 system, we identified genes involved in the core fucosylation pathway as positive regulators of cell-surface PD-1 expression. Inhibition of Fut8, a core fucosyltransferase, by genetic ablation or pharmacologic inhibition reduced cell-surface expression of PD-1 and enhanced T cell activation, leading to more efficient tumor eradication. Taken together, our findings suggest that blocking core fucosylation of PD-1 can be a promising strategy for improving anti-tumor immune responses.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CRISPR screen; PD-1; core fucosylation; tumor immunotherapy

Mesh:

Substances:

Year:  2017        PMID: 28768188     DOI: 10.1016/j.celrep.2017.07.027

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  59 in total

Review 1.  Breaking the Glyco-Code of HIV Persistence and Immunopathogenesis.

Authors:  Florent Colomb; Leila B Giron; Irena Trbojevic-Akmacic; Gordan Lauc; Mohamed Abdel-Mohsen
Journal:  Curr HIV/AIDS Rep       Date:  2019-04       Impact factor: 5.071

2.  Decreased Immunoglobulin G Core Fucosylation, A Player in Antibody-dependent Cell-mediated Cytotoxicity, is Associated with Autoimmune Thyroid Diseases.

Authors:  Tiphaine C Martin; Mirna Šimurina; Marta Ząbczyńska; Marina Martinic Kavur; Magdalena Rydlewska; Marija Pezer; Kamila Kozłowska; Andrea Burri; Marija Vilaj; Renata Turek-Jabrocka; Milena Krnjajić-Tadijanović; Małgorzata Trofimiuk-Müldner; Ivo Ugrina; Anna Lityńska; Alicja Hubalewska-Dydejczyk; Irena Trbojevic-Akmacic; Ee Mun Lim; John P Walsh; Ewa Pocheć; Tim D Spector; Scott G Wilson; Gordan Lauc
Journal:  Mol Cell Proteomics       Date:  2020-02-05       Impact factor: 5.911

3.  Targeting Glycosylated PD-1 Induces Potent Antitumor Immunity.

Authors:  Linlin Sun; Chia-Wei Li; Ezra M Chung; Riyao Yang; Yong-Soo Kim; Andrew H Park; Yun-Ju Lai; Yi Yang; Yu-Han Wang; Jielin Liu; Yufan Qiu; Kay-Hooi Khoo; Jun Yao; Jennifer L Hsu; Jong-Ho Cha; Li-Chuan Chan; Jung-Mao Hsu; Heng-Huan Lee; Stephen S Yoo; Mien-Chie Hung
Journal:  Cancer Res       Date:  2020-03-10       Impact factor: 12.701

4.  Structural basis of substrate recognition and catalysis by fucosyltransferase 8.

Authors:  Michael A Järvå; Marija Dramicanin; James P Lingford; Runyu Mao; Alan John; Kate E Jarman; Rhys Grinter; Ethan D Goddard-Borger
Journal:  J Biol Chem       Date:  2020-03-27       Impact factor: 5.157

5.  Appropriate aglycone modification significantly expands the glycan substrate acceptability of α1,6-fucosyltransferase (FUT8).

Authors:  Roushu Zhang; Qiang Yang; Bhargavi M Boruah; Guanghui Zong; Chao Li; Digantkumar Chapla; Jeong-Yeh Yang; Kelley W Moremen; Lai-Xi Wang
Journal:  Biochem J       Date:  2021-04-30       Impact factor: 3.857

6.  FUT8-mediated aberrant N-glycosylation of B7H3 suppresses the immune response in triple-negative breast cancer.

Authors:  Yun Huang; Hai-Liang Zhang; Zhi-Ling Li; Tian Du; Yu-Hong Chen; Yan Wang; Huan-He Ni; Kai-Ming Zhang; Jia Mai; Bing-Xin Hu; Jun-Hao Huang; Li-Huan Zhou; Dong Yang; Xiao-Dan Peng; Gong-Kan Feng; Jun Tang; Xiao-Feng Zhu; Rong Deng
Journal:  Nat Commun       Date:  2021-05-11       Impact factor: 14.919

7.  First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid Tumors.

Authors:  Khanh T Do; Laura Quan Man Chow; Karen Reckamp; Rachel E Sanborn; Howard Burris; Francisco Robert; D Ross Camidge; Conor E Steuer; John H Strickler; Amy Weise; Jennifer M Specht; Martin Gutierrez; Peter Haughney; Shawna Hengel; Christina Louise Derleth; Timothy A Yap
Journal:  Oncologist       Date:  2021-09-22

Review 8.  Applications of CRISPR Genome Editing to Advance the Next Generation of Adoptive Cell Therapies for Cancer.

Authors:  Samantha M Fix; Amir A Jazaeri; Patrick Hwu
Journal:  Cancer Discov       Date:  2021-02-09       Impact factor: 39.397

Review 9.  Glycosylation of Immune Receptors in Cancer.

Authors:  Ruoxuan Sun; Alyssa Min Jung Kim; Seung-Oe Lim
Journal:  Cells       Date:  2021-05-04       Impact factor: 6.600

Review 10.  FUT8 and Protein Core Fucosylation in Tumours: From Diagnosis to Treatment.

Authors:  Chengcheng Liao; Jiaxing An; Suqin Yi; Zhangxue Tan; Hui Wang; Hao Li; Xiaoyan Guan; Jianguo Liu; Qian Wang
Journal:  J Cancer       Date:  2021-05-13       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.